DiaMedica Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Der Gewinn von DiaMedica Therapeutics wird voraussichtlich um 8.2% pro Jahr zurückgehen, während der Jahresumsatz um 74.6% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 2.4% pro Jahr steigen.
Wichtige Informationen
-8.2%
Wachstumsrate der Gewinne
2.43%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 25.2% |
| Wachstumsrate der Einnahmen | 74.6% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 08 May 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Companies Like DiaMedica Therapeutics (NASDAQ:DMAC) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Preeclampsia Breakthrough Potential And Strong Cash Runway Will Support Future Value Creation
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a KLK1 protein therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?
Preeclampsia And Stroke Programs Will Drive Long Term Potential For This Biotech
Catalysts About DiaMedica Therapeutics DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing DM199, a recombinant KLK1 therapy, for vascular conditions such as preeclampsia, fetal growth restriction and acute ischemic stroke. What are the underlying business or industry changes driving this perspective?Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think DiaMedica Therapeutics (NASDAQ:DMAC) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...FDA puts DiaMedica's phase 2/3 trial for its stroke treatment DM199 on clinical hold
DiaMedica Therapeutics (NASDAQ:DMAC) on Wednesday said the U.S. FDA had placed a clinical hold on its phase 2/3 trial evaluating its product candidate DM199 for the treatment of a type of stroke called acute ischemic stroke. The trial, called ReMEDy2, was put on hold as three serious cases of low blood pressure in stroke patients were reported after they received an injection of DM199. The company said it had paused patient enrollment, and believes the low blood pressure events were due to the use of a different intravenous bag in the ReMEDy2 trial from the one used in the prior ReMEDy1 trial. "...the company is confirming the differences in drug absorption in the IV bags used in the ReMEDy1 trial compared to the ReMEDy2 trial and plans to work with the FDA to modify the ReMEDy2 trial protocol to adjust the DM199 IV dosing to more closely match the dosing in the ReMEDy1 trial, taking into account these differences", DMAC said. DMAC said that no such low blood pressure issues were reported in the ReMEDy1 trial.We're Not Very Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...We're Hopeful That DiaMedica Therapeutics (NASDAQ:DMAC) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...DiaMedica: Proven Stroke Drug In Asia, Headed To The U.S.
DMAC is a microcap biotech that has the first potential breakthrough stroke drug in 25 years, which addresses a $3.5 billion U.S. market. They initiated a phase 2/3 pivotal trial. Their drug, DM199, is the first synthetic version of a naturally occurring protein, KLK1. Porcine and human-derived KLK1 have been used for 20+ years in Asia to treat stroke/kidney disease. A near-term Asian strategic partner could provide a $5-$20 million upfront payment with a potential of $50+ million in milestone payments for DM199 distribution rights. Insider buying of 110K+ shares in Q3-2021 is a very positive signal. The average price target from 5 Wall Street analysts is $22, or 5x the current price. A recent capital raise eliminates concern over any future dilution. No capital should be needed until mid-2023 after the pivotal stroke study results are released and the kidney indications.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 5 | -76 | -67 | N/A | 3 |
| 12/31/2027 | N/A | -57 | -60 | -43 | 5 |
| 12/31/2026 | N/A | -46 | -46 | -40 | 5 |
| 3/31/2026 | N/A | -35 | -31 | -31 | N/A |
| 12/31/2025 | N/A | -33 | -29 | -29 | N/A |
| 9/30/2025 | N/A | -32 | -28 | -28 | N/A |
| 6/30/2025 | N/A | -30 | -26 | -26 | N/A |
| 3/31/2025 | N/A | -27 | -23 | -23 | N/A |
| 12/31/2024 | N/A | -24 | -22 | -22 | N/A |
| 9/30/2024 | N/A | -22 | -19 | -19 | N/A |
| 6/30/2024 | N/A | -20 | -20 | -20 | N/A |
| 3/31/2024 | N/A | -19 | -20 | -20 | N/A |
| 12/31/2023 | N/A | -19 | -19 | -19 | N/A |
| 9/30/2023 | N/A | -18 | -18 | -18 | N/A |
| 6/30/2023 | N/A | -17 | -15 | -15 | N/A |
| 3/31/2023 | N/A | -15 | -13 | -13 | N/A |
| 12/31/2022 | N/A | -14 | -12 | -12 | N/A |
| 9/30/2022 | N/A | -13 | -12 | -12 | N/A |
| 6/30/2022 | N/A | -14 | -12 | -12 | N/A |
| 3/31/2022 | N/A | -13 | -12 | -12 | N/A |
| 12/31/2021 | N/A | -14 | -12 | -12 | N/A |
| 9/30/2021 | N/A | -15 | -13 | -12 | N/A |
| 6/30/2021 | N/A | -14 | -12 | -12 | N/A |
| 3/31/2021 | N/A | -13 | -11 | -11 | N/A |
| 12/31/2020 | N/A | -12 | -9 | -9 | N/A |
| 9/30/2020 | N/A | -11 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -10 | -7 | -7 | N/A |
| 3/31/2020 | N/A | -10 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -11 | N/A | -9 | N/A |
| 9/30/2019 | N/A | -10 | N/A | -9 | N/A |
| 6/30/2019 | 1 | -9 | N/A | -10 | N/A |
| 3/31/2019 | 1 | -8 | N/A | -8 | N/A |
| 12/31/2018 | 1 | -6 | N/A | -6 | N/A |
| 9/30/2018 | 1 | -5 | N/A | -5 | N/A |
| 6/30/2018 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2018 | N/A | -4 | N/A | -4 | N/A |
| 12/31/2017 | N/A | -4 | N/A | -4 | N/A |
| 9/30/2017 | N/A | -4 | N/A | -4 | N/A |
| 6/30/2017 | N/A | -4 | N/A | -4 | N/A |
| 3/31/2017 | N/A | -3 | N/A | -3 | N/A |
| 12/31/2016 | N/A | -2 | N/A | -3 | N/A |
| 9/30/2016 | N/A | -2 | N/A | -2 | N/A |
| 6/30/2016 | N/A | -2 | N/A | -2 | N/A |
| 3/31/2016 | N/A | -1 | N/A | -2 | N/A |
| 12/31/2015 | N/A | -2 | N/A | -2 | N/A |
| 9/30/2015 | N/A | -2 | N/A | -1 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: DMAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: DMAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: DMAC wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: DMAC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Hohe Wachstumseinnahmen: DMAC wird im nächsten Jahr voraussichtlich keine Einnahmen haben.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von DMAC in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/18 19:57 |
| Aktienkurs zum Tagesende | 2026/05/15 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
DiaMedica Therapeutics Inc. wird von 13 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Kyle Bauser | Colliers Securities |
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |